aminoethylether)-N,N,NЈ,NЈ-tetraacetic acid (EGTA) 0.1, and HEPES 5 (pH 7.2 with KOH). The electrodes were constructed from borosilicate glass (WPI) using a micropipette puller (Narishige, Japan) and were heat-polished with a microforge (Narishige). The resistance of the electrode when filled with the pipette solution was 2-3 MW. Membrane currents were recorded with an Axopatch 200B amplifier (Axon Instruments, U.S.A.) and a Digidata 1322A (Axon Instruments). Currents were filtered at 2 kHz and digitized at 10 kHz. Capacitance and series resistance compensations were optimized. The pCLAMP 9.2 software (Axon Instruments) was used to generate voltage clamp protocols and analyze current traces.
Western Blot Analysis Cells were solubilized at 4°C in radio immunoprecipitation assay (RIPA) buffer (Sigma, U.S.A.) containing a protease inhibitor. Protein concentrations were determined with the Bradford protein assay (BIO-RAD). Equal amounts of proteins were separated on a 7.5% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gel and were transferred to nitrocellulose membranes (Whatman, Germany). Membranes were blocked in 10% skim milk overnight and incubated with anti-hERG antibody (Santa Cruz Biotechnology, U.S.A.), followed by horseradish peroxidase conjugated secondary antibody (Santa Cruz Biotechnology). The membranes were then developed using Western blotting luminal reagent (Santa Cruz Biotechnology) for electrochemiluminescence detection in LAS-1000 V1.5 (Fujifilm, Japan).
qRT-PCR (Quantitative Reverse Transcriptase Polymerase Chain Reaction) RNA isolation and reverse transcription reaction were performed using the PureLink TM RNA Mini kit (Invitrogen) and SuperScript TM II (Invitrogen), respectively. The hERG mRNA expression levels were quantified using qRT-PCR using LightCycler 1.0 (Roche, Germany). cDNA derived from hERG-CHO cells was amplified using LightCycler FastStart DNA Master SYBR Green (Roche) in the presence of primers specific for hERG and bactin. The qRT-PCR was performed with an initial pre-incubation step for 10 min at 95°C, followed by 40 cycles for denaturation at 95°C for 20 s, annealing at 60°C for 20 s and extension at 72°C for 20 s. The primers, 5Ј-TCAACCTGC-GAGATACCAACATG-3Ј; 5Ј-CTGGCTGCTCCGTGTC-CTT-3Ј and 5Ј-CTTCAACACCCCAGCCATGT-3Ј; 5Ј-GTG-GTACGACCAGAGGCATACA-3Ј were used for amplification of hERG 21) and b-actin, 22) respectively.
Statistical Analysis Data were expressed as meanϮstandard error of the mean (S.E.M.). Data analysis and curve fitting were performed with Clampfit 9.2 (Axon Instruments) and Origin 8.0 software (OriginLab). Statistical comparisons were made using a two-tailed Student's t-test. p-Values Ͻ0.05 were considered statistically significant.
RESULTS

Inhibition of hERG K ؉ ؉ Currents by Hirsutenone
The effect of hirsutenone on the hERG K ϩ current was assessed in CHO cells expressing hERG K ϩ channels using the whole-cell patch clamp technique. The hERG K ϩ currents were elicited from a holding potential of Ϫ80 mV by test pulses ranging from Ϫ60 to ϩ40 mV in 10 mV steps. Each test pulse had a duration of 4 s duration and was applied every 8 s. Each test pulse was followed by a repolarization step to Ϫ50 mV for 2 s to evoke tail current. Twenty micromolar hirsutenone was applied to the bath for 20 min after control currents were recorded. Hirsutenone reduced both hERG currents during I step (the depolarizing test pulse) and I tail (the repolarizing pulse) ( Fig. 1A) . Normalized currentvoltage (I-V ) relationships of both I step (left panel) and I tail (right panel) are illustrated in Fig. 1B , which shows that I step increased from Ϫ60 to ϩ10 mV, peaked around ϩ10 mV and then decreased with further depolarization. I tail was increased with depolarizing voltages and reached a plateau around ϩ30 mV. Hirsutenone reduced both I step and I tail amplitudes at all test potentials.
Concentration Dependence of hERG K ؉ ؉ Channel Blockade At the hirsutenone concentrations of 5, 10, 20, 30 and 50 mM, the peak amplitudes of I step and I tail were measured in the same cell and were normalized to the control value. Hirsutenone blocked both hERG I setp and I tail in a concentration-dependent manner. The fractional blockages in I step were 9.1Ϯ1.5%, 16.9Ϯ7.1%, 28.0Ϯ6.6%, 42.1Ϯ4.7% and 68.4Ϯ9.6%, and those in I tail were 13.3Ϯ3.1%, 29.5Ϯ2.9%, 42.2Ϯ10.2%, 55.89Ϯ8.8% and 83.7Ϯ10.8% in the 5, 10, 20, 30 and 50 mM hirsutenone groups, respectively (nϭ10, Fig. 1C insert). Compared with the control, hirsutenone showed significant concentration-dependent inhibitory effects on I step and I tail . To obtain the IC 50 of hirsutenone, concentration-response relationships of I tail were fitted using the Hill equation. The IC 50 of hirsutenone was 14.9Ϯ2.0 mM (nϭ10, Fig. 1C ). In addition, an irreversible inhibitory effect of hirsutenone was observed (data not shown).
Effects of Hirsutenone on hERG K ؉ ؉ Channel Kinetics
We evaluated the voltage dependence of activation by plotting normalized I tail as a function of voltage ( Fig. 1D ). Data were fitted with the Boltzmann function: Iϭ I max [1ϩexp(V 1/2 ϪV)/k] Ϫ1 , where I max , V 1/2 and k are the maximum amplitude, half-activation voltage and slope factor, respectively. In this protocol, hirsutenone changed neither the half-activation voltage nor the slope factor (V 1/2 : Ϫ3.6Ϯ2.8 mV and Ϫ2.9Ϯ1.8 mV; k: 9.3Ϯ1.9 and 10.3Ϯ1.8; in controls and after hirsutenone, respectively; nϭ10, pϾ0.05). These results indicated that the rate of activation was not changed after treatment with of 20 mM hirsutenone.
To measure steady-state inactivation, a special protocol was used to inactivate the channel at a holding potential of ϩ20 mV for 2 s, recover the channel from inactivation at various potentials from Ϫ120 to ϩ60 mV for 15 ms in 10 mV steps, and measure the resulting peak outward current at a constant ϩ20 mV in the absence and presence of 20 mM hirsutenone ( Fig. 2A ). In Fig. 2B , the inactivating outward current amplitude was normalized and plotted against the test pulse potential, producing the steady-state inactivation curve. This curve was fitted with a Boltzmann function, in which the V 1/2 values were Ϫ43.5Ϯ4.5 mV in the control and Ϫ37.4Ϯ4.9 mV in hirsutenone-treated samples; the corresponding k values were 19.6Ϯ4.2 and 19.8Ϯ4.2, respectively (nϭ10). Statistical significance was not detected with V 1/2 or k values. Hirsutenone did not significantly affect the halfmaximal inactivation voltages of the hERG channels; no significant shift was observed in the inactivation curve. The time course of channel inactivation was also assessed. To obtain the time constants of steady-state inactivation, the de-cays of the outward currents in Fig. 2A were fitted to single exponential functions and plotted against voltages ( Fig. 2C) . Although hirsutenone caused a slight decrease in the time constants of direct channel inactivation, the changes were not statistically significant.
To assess the onset rate of channel inactivation, a threepulse protocol was used. The channels were first inactivated by clamping the membrane at ϩ20 mV for 2 s, followed by a prepulse to Ϫ120 mV for 15 ms. This prepulse was sufficiently long to allow for the rapid recovery of channels from inactivation but short enough to prevent significant channel deactivation. Following the recovery prepulse, a series of test pulses were delivered to potentials ranging from Ϫ80 to ϩ60 mV, resulting in large, outward inactivating currents. The current traces at the onset of inactivation in the absence and presence of 20 mM hirsutenone are shown in Fig. 3A . The time constants for the onset of inactivation were obtained by fitting a single exponential function to the decaying current traces during the third pulse of the protocol. The time constants were significantly decreased in the presence of 20 mM hirsutenone (nϭ10, Fig. 3B ).
To determine the recovery from inactivation, the fully acti- vated I-V protocol was used. Each current was obtained through depolarization to ϩ20 mV for 2 s to inactivate the hERG channels, followed by varying repolarizing pulses to test potentials between Ϫ120 to ϩ30 mV in 10 mV steps. The prepulse potential at ϩ20 mV was sufficiently positive to induce full conductance of the hERG channels but also rendered a large number of the channels inactive. The recovery from inactivation current traces in the absence and presence of 20 mM hirsutenone are shown in Fig. 3C . The increasing phase of the tail current represented the rapid recovery of hERG channels from inactivated to open states. The time constants were obtained by fitting a single exponential function to the initial increase in tail current amplitude (nϭ10, Fig. 3D ). The time constants of recovery from inactivation were slightly small in the presence of 20 mM hirsutenone, but did not demonstrate significant changes.
Effect of Protein Kinase A (PKA), Protein Kinase C (PKC) and Protein Tyrosine Kinase (PTK) inhibitors on I tail Blockade by Hirsutenone
To further understand hERG K ϩ current blockade by hirsutenone and to investigate the involvement of PKA, PKC and PTK pathways in mediating hirsutenone-induced I tail depression, the effects of PKA, PKC and PTK inhibitors were investigated. Respectively, pre-treatment with 1 mM H-89, 1 mM Chelerythrine Chloride (CTC) and 80 mM Genestein (Gen) for 24 h did not alter the effects of hirsutenone on I tail in hERG-CHO cells (Fig. 4) .
Delayed Effects of Hirsutenone on hERG K ؉ ؉ Channel Expression
To study the effects of hirsutenone on hERG K ϩ channel protein trafficking, we investigated the effects of hirsutenone on channel expression using the Western blotting. hERG-CHO cells were incubated with either control or hirsutenone-containing medium (5, 10, 20, 30, 50 mM) for 24 h. In control medium, hERG channels showed protein bands at 135 kDa (immature, core-glycosylated channel protein) and 155 kDa (mature, fully glycosylated channel protein). There were no bands present at either size in non-transfected CHO cells (Fig. 5A ). Incubation with hirsutenone produced a concentration-dependent increase in the intensity of fully glycosylated channel protein (155 kDa), whereas the core-glycosylated channel protein (135 kDa) remained unchanged except at 30 and 50 mM, where the intensity of the 135 kDa band was increased (Fig. 5A) .
To further analyze the effect of hirsutenone on hERG K ϩ channel processing, the influence of hirsutenone on hERG mRNA levels was quantified using qRT-PCR. hERG-CHO cells were treated with either control or hirsutenone-containing medium (5, 10, 20, 30, 50 mM) for 24 h. The quantification of hERG mRNA levels was performed using the com-parative cycle threshold method, with the b-actin expression level as an internal control, and through subsequent ratio determination relative to samples from untreated hERG-CHO cells. In these analyses, 5, 10 and 20 mM hirsutenone did not affect gene expression, whereas 30 and 50 mM hirsutenone resulted in significant increases of hERG mRNA (nϭ4, Fig.  5B ).
To confirm that incubations with high concentrations (30, 50 mM hirsutenone) result in increases of hERG K ϩ channel surface and mRNA expression, current density was measured in hERG-CHO cells. The cells were incubated with control and 30 mM hirsutenone-containing medium for 24 h and current density was measured. On the day of experiment, cells were washed and placed in standard bath solution (control) and 30 mM hirsutenone containing bath solution (acute, 24 h pre-incubation) for electrophysiological recording. Current density was 30.09Ϯ11.13, 19.06Ϯ3.6 and 29.94Ϯ4.63 in cells treated with control, acute, and 24 h pre-incubation with 30 mM hirsutenone respectively. Acute treatment with 30 mM hirsutenone significantly reduced current density (nϭ8, pϽ0.01), although 24 h pre-incubation with 30 mM hirsutenone did not significantly affect current density (nϭ6, pϾ0.05) (Fig. 5C ). This same 24 h pre-incubation with 30 mM hirsutenone significantly affected hERG K ϩ channel expression but did not significantly affect current density.
DISCUSSION
To assess the cardiovascular safety of new drugs, their effects on hERG K ϩ channels are generally examined using a whole cell patch clamp method. Because hERG K ϩ channel blockade has the potential to cause extensive side effects, in addition to LQTS and arrhythmias, the test for drug-induced hERG K ϩ channel blockade is essential to drug development before doing the in vivo toxicological studies. 23) A number of drugs have been withdrawn from the market or failed in latestage clinical trials due to a side effect inducing cardiac arrhythmia. Therefore, understanding drug-hERG K ϩ channel interaction at a molecular level is necessary for rational drug design.
The present study showed that hirsutenone directly blocks hERG K ϩ channels in hERG-CHO cells. The blockage was significantly increased at the voltage (ϩ30 mV) at which the hERG K ϩ channel was fully activated (Fig. 1B) . These results suggested that hirsutenone blockage might occur via open-state blockage. However, no channel kinetics related to channel activation were changed (Fig. 1D ), indicating that hirsutenone may not block the hERG K ϩ channel when it is open. So, we also investigated the effects of hirsutenone on hERG K ϩ channel inactivation kinetics. Hirsutenone significantly decreased the time constants of onset of inactivation ( Fig. 3B ) although steady-state inactivation and recovery from inactivation properties were not significantly changed (Figs. 2, 3D) . These results indicate that the inactivation of hERG K ϩ channels was accelerated by hirsutenone and hirsutenone might also exhibit high affinity for the inactivated state.
Some drugs inhibit voltage-gated K ϩ channels via tyrosine phosphorylation of the channel protein. 24, 25) Therefore, we investigated whether phosphorylation mechanism was involved in hERG K ϩ channel blockade by hirsutenone. Preincubation with PKA, PKC and PTK inhibitor for 24 h did not prevent I tail blockade by hirsutenone (Fig. 4) . The above results suggest that the hERG K ϩ channel may be directly blocked by hirsutenone via promoting the inactivation process.
Many drugs induce action potential prolongation by indirectly reducing the hERG K ϩ channel protein trafficking rather than directly inhibiting the channel current. 10, 26) Some drugs inhibit both hERG K ϩ current and protein trafficking. 26) To investigate whether hirsutenone affects hERG K ϩ channel protein trafficking, hERG-CHO cells were incubated with hirsutenone for 24 h. We did not find any significant effects of hrisutenone on the immature form at 5, 10 and 20 mM, but the mature form at all test concentrations and the immature form at 30 and 50 mM was significantly increased (Fig. 5A) . These increases at high concentrations may be caused by an increase in gene expression.
We also investigated whether hirsutenone affects hERG K ϩ channel processing. Analyzing hERG mRNA levels, we found an increase of hERG gene expression after incubation with 30 and 50 mM hirsutenone (Fig. 5B) . A significant increase in hERG gene and surface expression was detected via qRT-PCR and Western blotting. However, these results are not consistent with the electrophysiological results. Therefore, to investigate the contradictory results, we compared hERG K ϩ current density in control, 30 mM hirsutenone (acute), and after 24 h pre-incubation (chronic) with 30 mM hirsutenone. The current density was significantly reduced in acute treatment, but was unaffected by chronic treatment (Fig. 5C ). These findings indicate that hirsutenone affects the hERG K ϩ channels via dual mechanisms; acute inhibition of hERG K ϩ channels and chronic drug-induced increase of hERG expression. Further studies are necessary to determine, whether increased hERG K ϩ channel expression could be compensated the current density reduction.
In this study, we found that hirsutenone directly inhibited hERG K ϩ currents in a concentration-dependent manner, with an IC 50 of 14.9 mM (Fig. 1C) . With regard to the relationship among the hERG K ϩ current blockade, QT prolongation and fatal arrhythmia, Redfern et al. 27) recommended a 30-fold safety margin between the maximal effective therapeutic plasma concentration and the IC 50 of hERG K ϩ channel. Based on this recommendation, the maximal therapeutic plasma concentration should be less than 0.5 mM. However, hirsutenone has demonstrated anti-inflammatory and immune modulatory effects between 10 to 50 mM concentrations in in vitro experiments. 15, [17] [18] [19] In vitro effective concentrations are higher than the recommended therapeutic plasma concentrations; therefore, if hirsutenone is used as an injected or orally administered drug there is an expected risk of QT prolongation and fatal arrhythmia. Although hirsutenone has the possibility of inducing a cardiac arrhythmia, its positive antiinflammatory and immune modulatory effects are too strong to recommend discontinuation of the drug. If we use hirsutenone as a topical ointment to treat inflammatory skin lesions like atopic dermatitis and contact dermatitis, we could minimize the side effects because the transcutaneous absorption rate is lower than 1% that of oral delivery or injection.
In conclusion, hirsutenone was shown to be a potent direct blocker of hERG K ϩ channels which functions by changing channel inactivation kinetics. In addition, hirsutenone affected hERG K ϩ channel trafficking and processing. Our results provide an understanding of the cardiovascular risk profile and safety margin of the new drug hirsutenone.
